Key result
Mendelian randomization links lipoprotein(a) to a causal role in myocardial infarction.
Answers are grounded in this paper and cite their sources.
Despite several observational studies showing that lipoprotein(a), or Lp(a), is associated with myocardial infarction (MI) 1, 2 , only circumstantial evidence exists regarding the causal nature of this association. Observational epidemiological studies, even with a sound prospective design, can provide hints to disease pathogenesis when the effect size is modest but cannot provide definitive evidence for causal relationships. Much of the current understanding of the causal factors in cardiovascular disease, such as the role of LDL, has been confirmed by randomized clinical trials (RCT) However, RCTs are not always feasible. In the case of Lp(a), the modest effect size and the lack of specific Lp(a) lowering therapy are major obstacles to obtaining causal evidence for its role in cardiovascular disease. In this issue of JAMA, Kamstrup and colleagues 5 provide insights using a "Mendelian randomization" approach and provide evidence for the causal role of Lp(a) in MI. This study elegantly demonstrates how Mendelian randomization can be used to improve the evidence for causality from observational studies and highlights the advantages and limitations of such an approach.
No takes yet. Share an insight, caveat, or question.
Thanassoulis et al. (2009) conducted an editorial in Myocardial infarction. Lipoprotein(a) was evaluated on Myocardial infarction. Lipoprotein(a) is suggested to have a causal role in myocardial infarction based on evidence from a Mendelian randomization approach.
Synapse has enriched 10 related papers. Consider them for comparative context: